Advertisement Pharmaceutical Business review - Page 2 of 5254 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 17, 2025

Harbour BioMed and BMS sign multi-specific antibody collab

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement focused on multi-specific antibody discovery and development.

Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of multi-specific antibodies. Credit: shisu_ka/Shutterstock.com.